Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Routine +

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

Arch Biopartners Doses First Patient in Phase II AKI Trial Amidst Dilution Concerns

By The Northwire Desk — AI Analysis May 22, 2026 · 06:50 ARCH · 0.445 Arch Biopartners Inc.
Executive Summary
  • Royal Columbian Hospital (RCH) has dosed its first patient in Arch Biopartners' ongoing Phase II clinical trial for LSALT peptide.
  • The trial targets cardiac surgery-associated acute kidney injury (CS-AKI).
  • RCH is the fourth active dosing site in Canada, with recruitment continuing at Toronto General, St. Michael’s Hospital, and University of Calgary.
  • Company is in feasibility discussions for four prospective sites in the United States and one additional site in Ontario.
  • Recruitment target remains 240 patients across a multi-center, randomized, double-blind, placebo-controlled study.
  • CEO Richard Muruve confirms steady progress toward establishing LSALT peptide as a new drug to reduce AKI incidence and dialysis needs.
Material Impact
  • The news represents expected clinical progression following the April 30 announcement that RCH began patient recruitment.
  • Dosing of the first patient is a standard operational milestone rather than a data readout or efficacy confirmation, limiting immediate upside potential.
  • No new safety concerns (SUSARs) were reported in previous updates, maintaining the status quo on risk profile.
  • The announcement does not alter the capital structure or financing needs immediately but confirms burn rate continues as expected for Phase II execution.
  • Given the stock price ($0.44) is significantly below the recent private placement price ($0.60 in April 2026), positive news has limited ability to reverse sentiment without data readouts.
ARCH · Price
Company Overview
  • Company: Arch Biopartners Inc., focused on therapies for acute kidney injury (AKI) and chronic kidney disease (CKD).
  • Flagship Project: LSALT peptide in Phase II trial for cardiac surgery-associated AKI (CS-AKI).
  • Secondary Asset: Cilastatin in Phase II trial for toxin-induced AKI.
  • Pipeline Expansion: CKD platform targeting IL-32 cytokine, acquired via Lipdro Therapeutics acquisition in November 2025.
  • Scientific Basis: LSALT targets DPEP1-mediated inflammation; preclinical data published in Cell (2019) and Science Advances (2022).
Read the original news release →

More from Arch Biopartners Inc.

Jun 04, 2026 · 07:41

Arch Biopartners Advances Dual AKI Pipeline Amid Steady Cash Burn and Dilutive Financing

Technical Study Apr 30, 2026 · 07:00

Arch Biopartners Clinical Execution Continues Amidst Severe Capital Erosion and Liquidity Concerns

Other Apr 02, 2026 · 05:45

Arch Biopartners Closes Non-Brokered Private Placement

Financings Mar 30, 2026 · 06:03

Arch Biopartners Closes $600K Lifeline as Stock Tests 52-Week Lows Amid Dilution and Trial Rollout

Financings Mar 24, 2026 · 09:13

Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Production / Operations Mar 20, 2026 · 07:05

Arch Biopartners Announces St. Michael's Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide

Other